Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
Accession Number
DB10769
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Description
Not Available
Synonyms
  • Japanese encephalitis vaccine
  • Japanese encephalitis vaccine IC51
  • Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
External IDs
IC-51 / IC51
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IxiaroInjection, suspension6 ug/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUs
IxiaroSuspension6 mcgIntramuscularValneva Austria Gmbh2009-12-29Not applicableCanada
IxiaroInjection, suspension6 ug/0.5mLIntramuscularVetter Pharma Fertigung GmbH & Co. KG2009-03-30Not applicableUs
IxiaroInjection, suspension6 [arb'U]/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
DZ854I04ZE
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
ActeosideThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldosterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionZika Virus Infection1
1WithdrawnNot AvailableEncephalitis, Japanese B1
2CompletedNot AvailableEncephalitis, Japanese B / Yellow Fever1
2CompletedPreventionDengue Fever / Dengue Hemorrhagic Fever1
2CompletedPreventionEncephalitis, Japanese B / Hepatitis A1
3Active Not RecruitingPreventionJapanese Encephalitis Virus Disease1
3CompletedNot AvailableEncephalitis, Japanese B1
3CompletedPreventionEncephalitis, Japanese B10
3CompletedPreventionEncephalitis, Japanese B / Hepatitis A1
3CompletedPreventionEncephalitis, Japanese B / Inflammation, Brain1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
3CompletedPreventionInflammation, Brain3
3CompletedPreventionN. Meningitidis Carriage1
3RecruitingPreventionHealthy Volunteers (Meningococcal Infection)1
4CompletedBasic ScienceEncephalitis, Japanese B / Japanese Encephalitis Vaccine1
4CompletedPreventionEncephalitis, Japanese B2
4CompletedPreventionEncephalitis, Japanese B / Mumps / Rubella / Rubeola1
4CompletedPreventionInflammation, Brain1
4Enrolling by InvitationPreventionHand, Foot and Mouth Disease (HFMD)1
4RecruitingPreventionJapanese Encephalitis Vaccine1
4Unknown StatusBasic ScienceCellular Immunity in the Elderly (Above 65y) After Primary Vaccination Against JE1
Not AvailableCompletedNot AvailableEncephalitis, Japanese B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular6 ug/0.5mL
Injection, suspensionIntramuscular6 [arb'U]/0.5mL
SuspensionIntramuscular6 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on January 27, 2020 20:48